On May 22, 2024 the opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients (APIs), small molecules, of the Porton company took place in Mengeš. This marks another milestone of Porton's globalization journey after the acquisition of J-STAR Research Inc., a US based CRO, in 2017.
Photo of the Ceremony
As the first foreign company who brought to Slovenia the real CDMO business in the field of small molecule APIs, Porton hopes to open new opportunities for growth, development and innovations and will be able to meet the customers’ growing demand on supply chain security and provide them with innovative and reliable services.
The opening ceremony was hold in the presence of Mr. Jernej Salecl, Director of General Industry, Entrepreneurship and Internationalisation Directorate at Ministry of the Economy, Tourism and Sport, Slovenia, Mr. Zhao Binghui, Counselor of the Chinese Embassy in Slovenia, and Mr. Ju Nianfeng (Oliver Ju), Chairman and CEO of Porton.
The initial investment of Porton totaled 50 million Euros. The brand new R&D facility covers a construction area of approximately 1,000 square meters, at which there are four Active Pharmaceutical Ingredients (API) process labs, six analytical labs, and a kilo-lab with OEB 4 (≥1µg/m³) standards , capable of operating under both non-GMP and GMP conditions. The labs are equipped to perform a wide range of reactions and processes, including enzymatic reactions, metals catalysis, pressure reactions(hydrogenation, carbonylation, etc.), and Cryogenic - high temperature reactions (-80°C to 200°C), which will be able to provide R&D services for the API project needs at various clinical stages.
Photo of the R&D facility
In addition to openness and reliability, dedication to innovation is the main principle of the company, which upon its arrival in Mengeš also responded to the needs of the local community and at the opening ceremony handed over a donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten.
Photo of Donation
Till now, Porton PharmaTech d.o.o., the Slovenian subsidiary of Porton Pharma Solutions Ltd., hired over 30 new employees and plans further growth. Porton has also started construction works of the pilot plant, from which in the future Porton will be able to supply its customers, well-known international pharmaceutical companies with the first batches of API's.
“The economies of both countries are very much connected and Porton's investment will significantly and holistically contribute to the further development of one of the most important segments of Slovenian economy – pharmaceutical industry.”Mag. Alenka Suhadolnik, Slovenia Ambasador in People's Republic of China
“Globalization is Porton's top priority strategy. For Porton, globalization means establishing R&D and manufacturing footprint in US and Europe, so as to meet our global client's increased needs on supply chain security, high quality and innovative and reliable services.”Mr. Oliver Ju, Chairman and CEO of Porton Pharma Solutions Ltd.
About Porton Pharma Solutions Ltd.
Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, TIDES, Biologics, ADCs from pre-clinical to commercial. As of December 31, 2023, we have a proven record for the delivery of more than 3,000 projects and established cooperation with more than 1,000 global clients.
About Porton PharmaTech D.O.O.
Porton PharmaTech d.o.o. is the European subsidiary of Porton Pharma Solutions Ltd. It is the first CDMO type of company in the pharmaceutical industry in Slovenia, dedicated to provide comprehensive services to customers, encompassing synthesis route development, process familiarization, analytical methods development and validation and process scale-up.
At Porton PharmaTech, d.o.o. customers are fully supported by an integrated project team committed to deliver services and products within expected timelines and quality.